The Trond Mohn Foundation has newly awarded 18 millions NOK to three cancer research projects, one of which is HUVAMER-project “HUVAMER – Home Treatment for Blood Cancer” led by Professor Dr. med. Bjørn Tore Gjertsen. The HUVAMER-project is aimed to develop a new combination of medications in treatment of acute myeloid leukemia (AML), with the READ MORE

On September 10-12th 2025, the Nordic AML Group Meeting took its place in Bergen – Norway. The meeting was organised by the Nordic AML Group (https://www.namlg.org/) chaired by Professor Dr. med. Bjørn Tore Gjertsen. The K.G. Jebsen-Centre for Myeloid Blood Cancer (CMYC) contributed as the local organising committee, the technical organizer for the meeting, and READ MORE